DANTHRON

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H8O4
Molecular Weight	240.2109
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=C2C(=O)C3=C(O)C=CC=C3C(=O)C2=CC=C1

InChI

InChIKey=QBPFLULOKWLNNW-UHFFFAOYSA-N

InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H

HIDE SMILES / InChI

Molecular Formula	C14H8O4
Molecular Weight	240.2109
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.sciencedirect.com/science/article/pii/B9780123864543012148
Curator's Comment: Description was created based on several sources, including https://ntp.niehs.nih.gov/ntp/roc/content/profiles/danthron.pdf

Danthron, a natural product, was originally extracted from the roots and rhizome of Polygonaceae plant. Danthron is an anthraquinone. Danthron has been widely administrated as a laxative since the 1900s. In the United States, danthron has been forbidden to continual use as laxative because it is considered to be a carcinogen. In the UK, it is not marketed alone but in combination with poloxamer 188 as co-danthramer and with docusate as co-danthrusate; in the UK, its use is strictly restricted to the elderly and to the terminally ill of all ages because of concerns about carcinogenicity and hepatotoxicity. It has only a limited role in the treatment of constipation.

Approval Year

Targets

Primary Target	Pharmacology	Potency
AMP-activated protein kinase, AMPK 17 Target ID: CHEMBL2096907 Sources: http://www.nature.com/aps/journal/v34/n8/pdf/aps201339a.pdf	Activator 1447
DNA topoisomerase II alpha 37 Target ID: CHEMBL3586 Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=9630566	Inhibitor 8504	14.0 µM [IC50]
Retinoid X receptor alpha 11 Target ID: CHEMBL2061 Sources: http://www.jbc.org/content/286/3/1868.full.pdf+html	Antagonist 2849	7.5 µM [Kd]
Apoptosis 156 Target ID: map04210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/19784869	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Constipation in terminally ill patients 1 Sources: http://www.drugs.com/uk/pdf/leaflet/676118.pdf	Curative		Withdrawn	Normax Approved Use Normax 50mg/60mg Capsules should only be used to relieve constipation in patients who are seriously ill. Normax 50mg/60mg Capsules work by encouraging normal bowel movements.

Doses

Dose	Population	Adverse events
25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/	unhealthy, 18 years Health Status: unhealthy Age Group: 18 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/	Other AEs: Leiomyosarcoma... Other AEs: Leiomyosarcoma Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/
25 mg 1 times / day single, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: single Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/638688/	unhealthy, 51 years Health Status: unhealthy Age Group: 51 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/638688/	Other AEs: Skin discoloration... Other AEs: Skin discoloration Sources: https://pubmed.ncbi.nlm.nih.gov/638688/
25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	unhealthy, 65 to 88 years Health Status: unhealthy Age Group: 65 to 88 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	Other AEs: Diarrhoea, Faecal incontinence... Other AEs: Diarrhoea (35%) Faecal incontinence (55%) Rash (15%) Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/	unhealthy, 80 and 69 years Health Status: unhealthy Age Group: 80 and 69 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/	Disc. AE: Contact dermatitis... AEs leading to discontinuation/dose reduction: Contact dermatitis Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/

AEs

AE	Significance	Dose	Population
Leiomyosarcoma		25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/	unhealthy, 18 years Health Status: unhealthy Age Group: 18 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/
Skin discoloration		25 mg 1 times / day single, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: single Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/638688/	unhealthy, 51 years Health Status: unhealthy Age Group: 51 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/638688/
Rash	15%	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	unhealthy, 65 to 88 years Health Status: unhealthy Age Group: 65 to 88 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/
Diarrhoea	35%	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	unhealthy, 65 to 88 years Health Status: unhealthy Age Group: 65 to 88 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/
Faecal incontinence	55%	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	unhealthy, 65 to 88 years Health Status: unhealthy Age Group: 65 to 88 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/
Contact dermatitis	Disc. AE	50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/	unhealthy, 80 and 69 years Health Status: unhealthy Age Group: 80 and 69 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741	UGT1A1 479 UGT1A6 343 UGT1A7 249 UGT1A9 423 UGT1A10 331

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1747-0285.2011.01089.x	no

Drug as victim

Target	Modality	Activity
UGT1A1 479	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxMjg3NjE3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	no
UGT1A6 343	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMzE2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	no
UGT1A9 423	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMzE5IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	no
UGT1A10 331	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMzIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	yes
UGT1A7 249	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMzE3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY455324	https://www.001chemical.com/chem/117-10-2
3B Scientific (Wuhan) Corp	3B1-00529	http://www.3bsc.com/index/pro_info.php?id=20741
AA Blocks	AA000DF4	https://www.aablocks.com/goods/Goods/detail?id=AA000DF4
Aaron Chemicals	AR000E6W	http://www.aaronchem.com/117-10-2
abcr GmbH	AB109119	http://www.abcr.com/shop/en/AB109119
AbMole Bioscience	M5549	http://www.abmole.com/products/danthron.html
Acadechem	ACDS-033112	http://www.acadechemical.com/product/107811
Accela ChemBio Inc	SY011288	http://www.accelachem.com/cn/search.html?keyword=SY011288&attname=GoodsCode
Achemica	ACMC-20mzuc	http://www.achemica.com/prodinfo/?id=227325
Achemo Scientific Limited	AC-23294	http://www.achemo.com/search/?Keyword=117-10-2
Acorn PharmaTech	ACN-035237	http://www.acornpharmatech.com/
Acros Organics	AC114830050	https://www.fishersci.com/shop/products/1-8-dihydroxyanthraquinone-90-95-acros-organics/AC114830050
Acros Organics	AC114831000	https://www.fishersci.com/shop/products/1-8-dihydroxyanthraquinone-90-95-acros-organics/AC114831000
Acros Organics	AC114835000	https://www.fishersci.com/shop/products/1-8-dihydroxyanthraquinone-90-95-acros-organics/AC114835000
AEchem Scientific Corp., USA	AE038910	http://www.aechemsc.com/info_products/AE038910.php
AHH Chemical co.,ltd	NP-0345	http://www.ahhchemical.com/product/NP-0345.html
AK Scientific, Inc. (AKSCI)	R229	http://www.aksci.com/item_detail.php?cat=R229
Alfa Aesar	A12001	https://www.alfa.com/en/catalog/A12001/
Alfa Chemistry	AP117102	https://reagents.alfa-chemistry.com/product/danthrone-cas-117-10-2-2185.html
Alichem	19150111	http://www.alichem.com/en/products/117-10-2.html
Ambinter	Amb1349101	http://www.ambinter.com/reference/1349101
Angene	AGN-PC-0JK6EB	http://www.angenechemical.com/productshow/AGN-PC-0JK6EB.html
Anward	ANW-17004	http://www.anward.com/pro_result/3917
Ark Pharm	AK208660	http://www.arkpharminc.com/products/117-10-2.html
Ark Pharma Scientific Limited	N-1556	http://www.arkpharmtech.com/product/241897.html
Aronis	ARONIS23892	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=1164
AvaChem Scientific	4000	http://www.avachem.com/productSearch.asp?4000
BioChemPartner	BCP31079	http://www.biochempartner.com/117-10-2-BCP31079
BioCrick	BCN6048	http://www.biocrick.com/Dantron-BCN6048.html
BioSynth	W-108572	https://www.biosynth.com/en/products/chemical-intermediates/advanced-intermediates/products/W-108572.html
BLD Pharm	BD55176	http://www.bldpharm.com/products/117-10-2.html
BOC Sciences	1246816-27-2	https://isotope.bocsci.com/product/1-8-dihydroxyanthraquinone-d6-cas-1246816-27-2-346722.html
Chem Scene	CS-4392	http://www.chemscene.com/117-10-2.html
ChemFaces	CFN99271	http://www.chemfaces.com/natural/Dantron-CFN99271.html
ChemMol	49426487	http://www.chemmol.com/chemmol/49426487.html
ChemMol	80101169	http://www.chemmol.com/chemmol/80101169.html
Chemspace	CSSB00016997201	https://chem-space.com/CSSB00016997201
Clearsynth	CS-T-89385	https://www.clearsynth.com/en/CST89385.html
CSNpharm	CSN17102	https://www.csnpharm.com/products/1,8-dihydroxyanthraquinone.html
DC Chemicals	DCE-005	http://www.dcchemicals.com//product_show-1_8_Dihydroxyanthraquinone.html
eNovation Chemicals	D409459	http://www.enovationchem.com/productDetails.asp?productID=D409459
Finetech	FT-0624445	http://www.finetechnology-ind.com/prod/detail/pub/117-10-2.html
FondChemical	FDB-2803	http://www.fondchemical.com/cpshow_cid_8_pid_2090.html
Glentham Life Sciences	GK4516	http://www.glentham.com/products/product/GK4516/
Hairui	HR135029	http://www.hairuichem.com/en/product/117-10-2.html
iChemical	EBD217295	http://www.ichemical.com/products/117-10-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00159216	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00159216
LGC Standards	DRE-C11961000	https://www.lgcstandards.com/US/en/p/DRE-C11961000
LGC Standards	LGCFOR0137.01	https://www.lgcstandards.com/US/en/p/LGCFOR0137.01
LGC Standards	MM0137.01	https://www.lgcstandards.com/US/en/p/MM0137.01
Matrix Scientific	58300	https://www.matrixscientific.com/058300.html
mcule	MCULE-5800615690	https://mcule.com/MCULE-5800615690/
MedChem Express	HY-B0923	https://www.medchemexpress.com/Danthron.html
Molcore	MC455324	https://www.molcore.com/product/117-10-2
MuseChem	I000607	https://www.musechem.com/product/I000607.html
Parchem	1364	http://www.parchem.com/chemical-supplier-distributor/1-8-Dihydroxy-Anthraquinone-002712.aspx
R&D Chemicals	417	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=7720
Renno Tech	RP28420	http://www.rennotech.com/product_show.asp?id=34036
Sigma-Aldrich	D108103_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/d108103?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	V900576_VETEC	https://www.sigmaaldrich.com/catalog/product/vetec/v900576?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S017455	http://www.sinfoobiotech.com/product/1020853
Smolecule	S525002	http://www.smolecule.com/products/s525002
Smolecule	S748642	https://www.smolecule.com/products/s748642
TCI (Tokyo Chemical Industry)	D0563	http://www.tcichemicals.com/eshop/en/us/commodity/D0563/index.html
THE BioTek	bt-264432	https://www.thebiotek.com/product/inhibitors/bt-264432
VladaChem	VL266649-100G	https://www.vladachem.com/product.php?products=117-10-2

PubMed

Title	Date	PubMed
Comparative developmental toxicity of environmentally relevant oxygenated PAHs.	2013-09-01	23684558
Danthron, an anthraquinone derivative, induces DNA damage and caspase cascades-mediated apoptosis in SNU-1 human gastric cancer cells through mitochondrial permeability transition pores and Bax-triggered pathways.	2011-01-14	21126053
Synchrotron radiation linear dichroism (SRLD) investigation of the electronic transitions of quinizarin, chrysazin, and anthrarufin.	2010-09-15	20541965
Danthron induces DNA damage and inhibits DNA repair gene expressions in GBM 8401 human brain glioblastoma multiforms cells.	2010-07	20369292
1,8-Dihydr-oxy-2,4,5,7-tetra-nitro-9,10-anthraquinone.	2010-04-24	21579207
Danthron induced apoptosis through mitochondria- and caspase-3-dependent pathways in human brain glioblastoma multiforms GBM 8401 cells.	2010-03	19784869
Anthraquinones danthron and quinizarin exert antiproliferative and antimetastatic activity on murine B16-F10 melanoma cells.	2010-02	20332452
Enzymatic reduction of complex redox dyes using NADH-dependent reductase from Bacillus subtilis coupled with cofactor regeneration.	2010-01	19662398
The coverage problem in video-based wireless sensor networks: a survey.	2010	22163651
1,8-Bis(tos-yloxy)-9,10-anthraquinone.	2009-12-04	21580139
Danthron inhibits the migration and invasion of human brain glioblastoma multiforme cells through the inhibition of mRNA expression of focal adhesion kinase, Rho kinases-1 and metalloproteinase-9.	2009-11	19787217
A high-throughput approach for identification of novel general anesthetics.	2009-09-24	19777064
Aloe-emodin-induced DNA fragmentation in the mouse in vivo comet assay.	2009-08	19559101
A 73-year-old man with long-term immobility presenting with abdominal pain.	2009-07-14	19597540
Structure-activity relationships of anthraquinones on the suppression of DNA-binding activity of the aryl hydrocarbon receptor induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin.	2009-03	19269596
Differential inhibition of matrix metalloproteinases-2, -9, and -13 activities by selected anthraquinones.	2009-03	19152226
Is senna laxative use associated to cathartic colon, genotoxicity, or carcinogenicity?	2009	20107583
Dissociative photoionization mechanism of 1,8-dihydroxyanthraquinone: an experimental and theoretical study.	2008-10-30	18828582
Study of interactions of anthraquinones with DNA using ethidium bromide as a fluorescence probe.	2008-06	17825605
On the interaction of the anthraquinone barbaloin with negatively charged DMPG bilayers.	2008-04-15	18318556
Solvent effect on the physical quenching of singlet molecular oxygen by p-quinones.	2008-04	18385892
Voltammetric Behavior of o-Nitrophenol and Damage to DNA.	2008-03	19325751
Towards reconciling structure and function in the nuclear pore complex.	2008-02	18228033
Potential benefits of non-pharmacological therapies in fibromyalgia.	2008	19088863
Initial in vitro screening approach to investigate the potential health and environmental hazards of Enviroxtrade mark - a nanoparticulate cerium oxide diesel fuel additive.	2007-12-05	18053256
Simultaneous determination and pharmacokinetic studies of aloe emodin and chrysophanol in rats after oral administration of Da-Cheng-Qi decoction by high-performance liquid chromatography.	2007-07	17370297
Antiprotozoal activity of Senna racemosa.	2007-06-13	17481835
Simultaneous quantification of five anthraquinones in rat plasma by high-performance liquid chromatography with fluorescence detection.	2007-05	17294506
The right dose for every sex.	2007-04	17124606
Anthranoid laxatives influence the absorption of poorly permeable drugs in human intestinal cell culture model (Caco-2).	2007-04	17098405
Reactivity of aromatic amines with triplet 1,8-dihydroxyanthraquinone: a laser flash photolysis study.	2007-01	16815083
Laxatives for the management of constipation in palliative care patients.	2006-10-18	17054172
Intramolecular hydrogen bonding in 1,8-dihydroxyanthraquinone, 1-aminoanthraquinone, and 9-hydroxyphenalenone studied by picosecond time-resolved fluorescence spectroscopy in a supersonic jet.	2006-10-12	17020367
Microbial transformation of amino- and hydroxyanthraquinones by Beauveria bassiana ATCC 7159.	2006-10	17067178
Defensive components in insect eggs: are anthraquinones produced during egg development?	2006-09	16835809
Electrocoagulation of quinone pigments.	2006-07-14	17971722
Interaction of anthracene and its oxidative derivatives with human serum albumin.	2006	16404478
Oxoazabenzo[de]anthracenes conjugated to amino acids: synthesis and evaluation as DNA-binding antitumor agents.	2005-07-21	16029036
[Toxic effects of 1,8-dihydroxyanthraquinone on Daphnia magna].	2005-06	16180778
Electrochemical studies of danthron and the DNA-danthron interaction.	2005-04-01	15792857
Serially balanced designs for two sets of treatments.	2005	15796295
Growth responses of Cassia obtusifolia toward human intestinal bacteria.	2004-07	15261390
Danthron (1,8-dihydroxyanthraquinone).	2004	21089845
Methotrexate for ankylosing spondylitis.	2004	15266537
1,8-Dihydroxyanthraquinone anchored on silica gel: synthesis and application as solid phase extractant for lead(II), zinc(II) and cadmium(II) prior to their determination by flame atomic absorption spectrometry.	2002-10-16	18968796
Danthron (1,8-dihydroxyanthraquinone).	2002	15323026
Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.	1996-09-03	8790401
Hydroxyquinones are competitive non-peptide inhibitors of HIV-1 proteinase.	1995-11-15	7492599
Inhibitors of human immunodeficiency virus integrase.	1993-03-15	8460151
Screening for new compounds with antiherpes activity.	1984-10	6517562

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose for adults is one to three capsules at bedtime. The usual dose for children aged 6-12 years is one capsule at bedtime. Normax 50mg/60mg Capsules are not recommended for use by children under 6 years of age. This product should be taken orally (by mouth). You must swallow the capsules whole with a drink of water. The capsules must not be crushed or chewed. Normax 50mg/60mg Capsules normally begin to work 8 hours after the dose is taken.

Route of Administration: Oral

In Vitro Use Guide

10 uM danthron reduces growth of B16-F10 melanoma by 83%

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:51:33 GMT 2025` Edited by `admin` on `Mon Mar 31 17:51:33 GMT 2025`
Record UNII	Z4XE6IBF3V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DANTRON

Preferred Name

English

DANTHRON

Common Name

English

1,8-DIHYDROXYANTHRACENE-9,10-DIONE

Systematic Name

English

CHRYSAZIN

Common Name

English

DITHRANOL IMPURITY B [EP IMPURITY]

Common Name

English

NSC-38626

Code

English

DANTHRON [MI]

Common Name

English

Dantron [WHO-DD]

Common Name

English

DANTRON [MART.]

Common Name

English

NSC-646568

Code

English

DORBANE

Brand Name

English

dantron [INN]

Common Name

English

DANTHRON [HSDB]

Common Name

English

1,8-Dihydroxyanthraquinone

Systematic Name

English

DANTRON [IARC]

Common Name

English

ISTIZIN

Brand Name

English

PILULES VINCHY N.F.

Brand Name

English

DANTHRON [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C45177